Clinical Trial Results Data
Buy and sell clinical trial results data data. Phase I-IV outcomes, adverse events, efficacy endpoints — trial data is the most expensive medical data to generate from scratch.
No listings currently in the marketplace for Clinical Trial Results Data.
Find Me This Data →Overview
What Is Clinical Trial Results Data?
Clinical trial results data encompasses Phase I through Phase IV outcomes, adverse events, efficacy endpoints, and patient-level information generated during the drug development process. This data represents the most expensive medical information to generate from scratch, making it highly valuable for pharmaceutical sponsors, contract research organizations (CROs), and regulatory bodies. The data includes patient demographics, treatment responses, safety profiles, and longitudinal health records that inform efficacy claims and regulatory submissions. As pharmaceutical companies increasingly adopt synthetic controls and digital-twin models alongside traditional trial designs, the market for both real and synthesized clinical trial data has expanded significantly.
Market Data
USD 47.18 billion
U.S. Clinical Trials Market Size (2025)
Source: Precedence Research
USD 88.16 billion
Projected U.S. Market by 2035
Source: Precedence Research
USD 96.5 million
Synthetic Clinical Trial Data Market (2026)
Source: Future Market Insights
USD 518.1 million
Synthetic Data Forecast (2036)
Source: Future Market Insights
More than 54%
Phase III Revenue Share (2025)
Source: Precedence Research
Who Uses This Data
What AI models do with it.do with it.
Synthetic Control Arms
Generated cohorts eliminate the need for physical control groups in rare disease studies, allowing sponsors to accelerate enrollment timelines and offer guaranteed active treatment to all participants.
Feasibility Simulation & Trial Design
Pharmaceutical companies and CROs use clinical trial results data to model patient recruitment challenges, predict enrollment patterns, and validate study protocol designs before patient recruitment begins.
Regulatory Submissions & Evidence Generation
Sponsors leverage trial results data—particularly tabular patient-level formats—for FDA submissions, health technology assessments, and payer negotiations to support efficacy claims and reimbursement decisions.
Privacy-Protected Data Sharing
Academic centers and regulators use de-identified clinical trial results data for meta-analyses, safety signal detection, and comparative effectiveness research without exposing individual patient information.
What Can You Earn?
What it's worth.worth.
Patient-Level Tabular Data
Varies
Most common format; holds 42% market share due to regulatory compatibility with existing SAS ecosystems and CDISC standards.
Longitudinal & Multimodal Records
Varies
Advanced formats command premium pricing but require custom engineering and updated validation tools; slower adoption in legacy workflows.
Synthetic Clinical Trial Data
Varies
Emerging premium segment growing at 18.3% CAGR; pricing varies by geographic region, data complexity, and regulatory validation requirements.
What Buyers Expect
What makes it valuable.valuable.
CDISC Compliance & Statistical Integrity
Data must map perfectly to Clinical Data Interchange Standards to prevent format conversion errors during regulatory filing. Tabular structures enable faster preliminary approvals from FDA data inspectors.
Complete Adverse Event Documentation
Comprehensive safety records including treatment-related events and severity classifications are mandatory. Shared clinical study reports must contain significantly more harm data than journal publications alone.
Temporal Integrity & Time-Series Insights
Patient histories must preserve longitudinal relationships and timeline accuracy. Complex multimodal formats require clean data structures to retain critical time-series information for biostatistical analysis.
Algorithmic Transparency & Source Documentation
Weak documentation of data generation methods can affect final regulatory assessment of trial validity. Regulatory bodies demand clear methodology disclosure, especially for synthetic cohorts.
Companies Active Here
Who's buying.buying.
Acquire Phase I-IV trial results data to accelerate drug development, validate efficacy endpoints, and generate regulatory submissions. Use synthetic controls to replace traditional placebo arms.
Leverage clinical trial results data for feasibility studies, patient matching algorithms, and baseline cohort simulation. Renamed entities like Clario offer comprehensive trial management across therapeutic areas.
Evaluate reimbursement claims using clinical trial results data. Remain skeptical of purely synthetic efficacy evidence but use generated patient profiles for internal modeling and health economics analysis.
Perform meta-analyses on efficacy and safety using individual patient data (IPD) and clinical study reports (CSRs). Share de-identified trial results for comparative effectiveness research.
FAQ
Common questions.questions.
What is the difference between real clinical trial data and synthetic trial data?
Real clinical trial results data comes from actual patient enrollment in Phase I-IV studies and includes genuine adverse events, efficacy endpoints, and individual patient outcomes. Synthetic clinical trial data is statistically generated using generative models, digital twins, or Bayesian synthesis methods to simulate patient cohorts and outcomes. Real data commands premium pricing because it is expensive to generate from scratch, while synthetic data is emerging as a cost-effective alternative for regulatory modeling and control arms, growing at 18.3% CAGR.
Why is Phase III data more valuable than other phases?
Phase III trials represent the largest, most rigorous efficacy studies required for regulatory approval. Phase III accounted for more than 54% of U.S. clinical trials market revenue in 2025, reflecting its critical role in supporting FDA submissions and reimbursement decisions. Regulators and payers weight Phase III evidence most heavily when evaluating drug efficacy claims.
What data format do regulatory agencies prefer?
Patient-level tabular data holds 42% of the synthetic clinical trial data market in 2026 because it maintains backward compatibility with legacy SAS ecosystems and maps perfectly onto CDISC standards. Regulators prefer flat-file structures for straightforward audits and faster preliminary approvals. Advanced longitudinal or multimodal formats strip temporal relationships when compressed and frequently break older visualization tools, causing submission delays.
Which therapeutic areas generate the most trial data revenue?
Oncology captured the largest indication share at around 26% of U.S. clinical trials market revenue in 2025. Other major therapeutic areas include autoimmune conditions, pain management, CNS conditions, obesity, cardiovascular disease, and diabetes. Rare disease oncology trials particularly benefit from synthetic control arms.
Sell yourclinical trial resultsdata.
If your company generates clinical trial results data, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.
Request Valuation